Fermer le menu


Member of Lyonbiopole


Transgene, part of Institut Mérieux, is a publicly traded French biotechnology company focused on designing and developing targeted immunotherapies for the treatment of cancers and infectious diseases. Transgene’s programs utilize viral vector technology with the goal of indirectly or directly killing infected or cancerous cells.

The Company’s lead clinical-stage programs are: TG4010 for non-small cell lung cancer, Pexa-Vec for liver cancer and TG4001 for HPV-positive head and neck cancers. The Company has several other programs in clinical and pre-clinical development.

Transgene also owns Invir.IO(TM), a new technology platform dedicated to the design of the next generation of oncolytic viruses. These multifunctional viruses are aimed at modulating the tumor micro-environment.

The Company is based in Strasbourg, France, and has additional operations in Lyon, in China and in the U.S.


Strategic application domain: Human Medicine

Application market: Infectious Diseases, Oncology

Type of activity: Therapeutics, Pharma or Biotech

Technologies: Cell Therapy - Stem cells - Cell Biology - Biobanking, Molecular Biology & Nucleic acid, Vaccine

Created on dec. 30th, 1979 - 168 employees



400 Boulevard Gonthier d'Andernach Parc d'Innovation 67405 Illkirch-Graffenstaden



Vous devez être connecté et membre de Lyonbiopôle pour voir les contacts.